ClinicalTrials.gg
RecruitingNCT05423275Updated Dec 9, 2024

Light and Ion Maintenance In Treatment for Depression (LIMIT-D): Feasibility Study

An interventional study of Negative ion therapy and Light therapy in Major Depressive Disorder, Recurrent, in Remission, sponsored by University of British Columbia. Recruiting at 1 site in Canada. Open to participants aged 19 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-12-09.

Sponsored by University of British Columbia · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
19 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Depressive Disorder, Major by University of British Columbia — 5 open to participants now, 7 under way, none of them phase 3. Depressive Disorder, Major · University of British Columbia.

Planned enrollment
5th of 15
100 · median 72
Started
2023
the only one that year
No phase
12 of 16
4 open now
Registered
13th of 16
by date

Among the 16 studies in Depressive Disorder, Major by University of British Columbia, this one is the 5th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2023, is one of 12 with no phase, and was the 13th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

5 of the 16 studies in Depressive Disorder, Major by University of British Columbia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 19 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Depressive Disorder, Major by University of British Columbia, or all of them as a file.
02

Study summary

Antidepressants are widely used as first-line treatments for major depressive disorder (MDD). Clinical guidelines recommend 6-24 months of "maintenance" antidepressant treatment, after patients achieve symptom remission, to prevent relapse but many people stop antidepressants too soon relapse into another depressive episode. We will test non-medication treatments, negative ion therapy and light therapy, to see they can substitute for antidepressants to prevent relapse. This is a "feasibility" study to see if participants use study treatments properly, before doing a larger, definitive trial. In this 28-week study, 100 participants with MDD who are in remission with antidepressants will be treated with light therapy or negative ion therapy (with half of devices active and half inactive) while slowly discontinuing the antidepressant, and monitored for relapse.

Read the detailed description

The purpose of this study is to evaluate the feasibility of a multicentre, randomized, trial of light therapy and negative ion therapy as substitutes for antidepressants for maintenance treatment for patients with recurrent major depressive disorder (MDD).

The study design for this feasibility study mirrors the full LIMIT-D protocol: a 28-week, double-blind (participant and outcome rater) relapse prevention study with 100 participants randomized 1:1 to one of two study treatments, light therapy or negative ion therapy, and assessed for relapse over 28 weeks. Half the study devices are modified to be inactive. After 2 weeks of study treatment, the participant's antidepressant will be tapered and discontinued between Week 2 and Week 8.

Participants are assessed for relapse at each scheduled study visit (every 2 weeks during antidepressant taper until week 8, then every 4 weeks until end of study treatment at Week 28) by blind outcome raters. In addition, they complete an online Personal Health Questionnaire (PHQ-9) self-rated depression symptom scale bi-weekly; if total score is 10 or higher OR the suicide item score is 2 or higher, participants are booked for a relapse-assessment visit and relapse-verification study visit at least 1 week apart. Relapse will be defined as any of the following:

  1. MADRS total score 20 or higher for at least 2 consecutive weeks and Diagnostic and Statistical Manual (DSM-5) criteria for major depressive episode at the Relapse-Verification visit.
  2. Hospitalization for worsening of depression.
  3. Suicidal ideation with intent or plan, or suicidal behaviour.
  4. Any change in treatment for depression (e.g., starting an antidepressant).

At each visit, clinician-rated and self-rated symptom, side effect, and functioning measures are completed. The primary feasibility outcome is recruitment rate; secondary feasibility outcomes include adherence to study treatment, successful discontinuation of antidepressants rate, and all-cause dropout rate. Secondary clinical outcomes include relapse rate, time to relapse, adverse events, and safety profiles.

Participants will wear an actigraph at home during the 28-week study treatment period to assess sleep, light and activity/circadian rhythms. There is a final observational visit by Zoom videoconference at Week 52.

03

Conditions studied

  • Major Depressive Disorder, Recurrent, in Remission

Keywords

  • antidepressants
  • discontinuation
  • relapse prevention
  • light therapy
  • negative ions
  • depression
04

Who can participate

Ages eligible
19 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnostic and Statistical Manual () criteria for MDD, as determined by the Structured Clinical Interview for DSM-5 (SCID).
  • Taking a antidepressant at approved doses (Table 1), with dose unchanged in the past month.
  • Participant desire to discontinue antidepressant treatment because of adverse effects or other reasons;
  • In remission as defined by score ≤10 on the clinician-rated Montgomery-Asberg Depression Rating Scale (MADRS) at both the screening visit and baseline visit, at least 2 weeks apart.
  • Willing and able to complete self-report and online assessments including sufficient fluency in English or French.

Exclusion criteria

Exclusion Criteria:

  • Any psychiatric diagnosis other than MDD that is considered the primary diagnosis, including Bipolar I or Bipolar-II (lifetime). Note that comorbid anxiety disorders (e.g., generalized anxiety disorder, social anxiety disorder) will not be excluded if the anxiety disorder is not the primary diagnosis.
  • Diagnosis of MDD with seasonal pattern (i.e., seasonal affective disorder, SAD) or with psychotic features (lifetime).
  • Significant personality disorder diagnosis [e.g., antisocial] by MINI and clinical assessment.
  • High suicidal risk, defined by clinician judgment.
  • History of alcohol or substance use disorder, with a severity of at least moderate or severe, within 6 months before screening.
  • Significant neurological disorders, head trauma, or other unstable medical conditions.
  • Regular use of psychotropic medication other than an antidepressant or benzodiazepines (e.g., antipsychotics, mood stabilizers); Note - Stimulant medications for Attention-Deficit Hyperactivity Disorder are allowed if dose is stable in past month.
  • History of severe antidepressant discontinuation effects.
  • Retinal disease or other eye condition (e.g., macular degeneration) precluding the use of bright light treatment.
  • Use of photosensitizing medication (thioridazine, chloroquine, 8-methoxypsoralen) within 1 week of baseline visit.
  • Initiated formal psychotherapy (e.g., cognitive-behavioural therapy) within 3 months of Visit 1, or who plan to initiate psychotherapy during the study.
  • Continued use of any other evidence-based treatment for depression.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Negative ion therapy

    High density negative ions at 3.4 trillion ions per second with no detectable ozone, used for 30 minutes as soon as possible after awakening, preferably between 7:00-8:00 am.

    Device: Negative ion therapy

  • Active comparator
    Light therapy

    4000 Kelvin white fluorescent light rated at 10,000 lux at 14 inches from screen to cornea, with an ultraviolet filter, used for 30 minutes as soon as possible after awakening, preferably between 7:00-8:00 am.

    Device: Light therapy

Interventions

  • DeviceNegative ion therapy

    Negative ion generator

  • DeviceLight therapy

    Fluorescent light box

06

What researchers measure

Primary outcomes

  1. Recruitment rate

    The number of participants entered into the study during the recruitment period.

    Time frame: 36 months

Secondary outcomes

  1. Adherence to study treatment

    Percentage of scheduled time that participants use the study treatment

    Time frame: 28 weeks

  2. Rate of stopping antidepressants

    Rate of success in tapering and discontinuing antidepressants

    Time frame: 8 weeks

  3. All-cause dropout rate

    Rate of dropouts from the study for any cause

    Time frame: 28 weeks

Other outcomes

  1. Time to relapse

    Time to protocol-defined relapse, based on survival analysis

    Time frame: 28 weeks

  2. Relapse rate

    Rate of relapses, based on survival analysis

    Time frame: 28 weeks

  3. Adverse events

    Number and severity of adverse events

    Time frame: 28 weeks

  4. Serious adverse events

    Number of serious adverse events including hypomanic mood switch

    Time frame: 28 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Dec 2026, 45 months after the start.

Of 654 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 45 months is above that.

Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2022
First posted
Jun 21, 2022
StartActual
Mar 13, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2027
Last update
Dec 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05423275
Collaborators
University of Toronto, Université de Montréal, Canadian Institutes of Health Research (CIHR), McMaster University, Ontario Brain Institute, Centre for Addiction and Mental Health
Responsible party
Raymond Lam (Principal Investigator, University of British Columbia) — Principal investigator
First posted
Jun 21, 2022
Start date
Mar 13, 2023
Primary completion
Dec 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Dec 9, 2024

Study contacts

Vanessa Evans, BSc
Contact
vanessa.evans@ubc.ca
604-822-8102
Raymond W Lam, MD
principal investigator · University of British Columbia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion